This one is very risky! Achilles Therapeutics –– UK based bio | Primor Investment Group

This one is very risky!

Achilles Therapeutics –– UK based biopharma company, focuses on developing drugs based on T-cell therapy for the treatment of multiple types of malignant tumours.
*not an investment advice

Ticker –– ACHL
IPO listing date: 31/03/2021
IPO size: $175 million
Market cap: $731 million
Listing price range: $17 – $19
Underwriters: JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co., Kempen & Co.

Highlights:
- Achilles Therapeutics created and patented PELEUS –– a platform that uses sophisticated statistical algorithms to process data from TRACERx database
- Achilles Therapeutics managed to raise $165.90M , from investors like Syncona Portfolio Limited, RA Capital Management, Forbion Capital Fund IV Cooperatief UA, and Baker Bros. Advisors LP.
- The global CAR-T cell therapy market is valued at $387.1 million in 2020 and a CAGR is expected to be 32.5% over the next 10 years
- Rising cancer incidence and an increase in the number of patients not responding to alternative treatments are expected to drive the growth of the global CAR-T cell therapy market
- Despite no revenue, and thanks to investments the company has $177.8 million in cash and $29.5 million in liabilities.

Downsides
- The company has no revenue . Whereas the expenses on research and development have increased by 157% over the past year
- Clinical development is a long and costly process with uncertain outcomes, and the results of earlier studies may not anticipate the results of future clinical trials.
- Any of their future products could cause undesired side effects that could stop their clinical development at any phase

https://achillestx.com/